Skip to main content

Vericel

Vericel Corp is an American advanced cell therapy biopharmaceutical company producing regenerative medicine products for sports medicine and severe burn care. The company manufactures and markets MACI, an autologous cellular scaffold for cartilage repair, alongside Epicel, a cultured epidermal autograft for severe burn treatment. Principal revenues stem from commercial sales of custom-manufactured cell therapy treatments directly to surgical health systems and specialized burn centers. Core end markets serve orthopedic surgeons, sports medicine clinics, reconstructive burn surgeons, and surgical hospitals across the United States. Vericel holds a market-leading position in advanced autologous cell therapy for cartilage repair and severe burn care in the US healthcare market. The corporation is headquartered in Cambridge, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.

10 of the funds FundTelligence covers report a position in Vericel.

Legal name
Vericel Corp
Sector
Health Care
Country
United States
Funds holding it
10

Funds holding Vericel

Showing the 8 largest of 10 funds holding it.

Loading...